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High incidence of cardiovascular
events in patients with rheumatoid
arthritis
Rheumatoid arthritis (RA) is associated with higher risk for
cardiovascular disease (CVD) in comparison with the general
population.1 Traditional cardiovascular (CV) risk factors only
partially explain the higher risk for CVD.2 There is increasing
evidence that inflammation explains the enhanced CV risk in
RA, as inflammation has a pivotal role in the development of
atherosclerotic disease and this might be the link between
increased atherosclerotic CVD and RA.3 Other RA-related
factors might be undertreatment of CV comorbidity,1 and the
use of non-steroidal anti-inflammatory drugs (NSAIDs) or
selective cyclo-oxygenase 2 inhibitors.4 5
The objective of this prospective observational study was to
determine the incidence of CV events in patients with RA in
comparison to the general Dutch population, where the
incidence of CV events is 1% per year.6
Between September 2003 and August 2004 three question-
naires were sent to all patients with RA of the Departments of
Rheumatology of the Jan van Breemen Institute and of the VU
University Medical Center, Amsterdam, The Netherlands.
A total of 12 532 questionnaires were sent to 4125 patients
with RA. In all, 2099 patients (51%) returned at least 1
questionnaire and 1036 patients (25%) returned 3 question-
naires, comprising 1557 patient years. The annual incidence of
CV events was 2.6 (95% CI 1.8 to 3.4) per 100 patient years. CV
events occurred in 41 patients: 19 patients experienced coronary
events, 14 patients experienced cerebrovascular events and 8
patients experienced peripheral arterial events (table 1).
We observed a more than twofold increase in the incidence of
CV events in RA in comparison to the general Dutch
population. The age-adjusted incidence of ischaemic heart and
cerebrovascular diseases in the general Dutch population was
1.0%,7 versus 2.6% in our RA population. As the RA population
encompassed relatively more women than the general popula-
tion our findings probably underestimate the true CV risk in
RA. As expected, established CV risk factors as higher age, male
gender, smoking and (family) history for CVD as well as statin
use, were associated with a higher risk for CVD.
Patients with CV events used a lower dose of methotrexate
than patients without CV events, which is in line with other
studies,8 demonstrating the CV protective effect of methotrex-
ate, probably mediated by inflammation suppression.9
The observed association between acetaminophen use and
antihypertensive use, might be due to the induction of
hypertension mediated by cyclo-oxygenase 2 inhibition.10 This
observation confirms earlier literature findings and necessitates
prospective investigations.
Cyclo-oxygenase 2 inhibitors and most NSAIDs are associated
with an increased CV risk.6 In the present study patients with
CV events used less NSAIDs prior to the event in comparison to
the patients without CV events. This is probably the result of
restrained prescriptions of cyclo-oxygenase 2 inhibitors and
NSAIDs to patients who were high risk for CVD and
demonstrates the potentially strong effects of unmeasured
confounding in observational studies.
Two limitations of this study should be discussed. Firstly, the
relatively low response rate of 51% could result in a selection
bias. Therefore, we compared the baseline characteristics
between the responders and non-responders and found no
differences rendering this bias unlikely. Secondly, the small
number of events in our case-control substudy makes it difficult
to reach final conclusions about CV risk factors. Future studies
are needed to further elucidate these topics.
Altogether, this study reveals a doubled incidence of CV
events in RA in comparison to the general Dutch population,
strengthening the case for CV risk management in RA.
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Table 1 Characteristics of patients with rheumatoid arthritis (RA) with and without cardiovascular (CV)
events
Patients with CV
events
Patients without CV
events p Value
No. of patients with RA 41 2058
Mean age, years (range) 72 (56–84) 61 (19–94) ,0.001
No. aged 60 years or older 36 (88) 1083 (53) ,0.001
No. of females (%) 23 (56) 1157 (73) 0.02
Duration of RA in years (%):
,2 1 (4) 76 (5) 1.000
2–10 12 (43) 676 (49) 0.53
.10 15 (54) 631 (46) 0.40
Unknown 13 (32) 675 (33)
No. of patients with history of GI event(s) (%) 7 (22) 175 (11) 0.04
No. of patients without history of GI event(s) 25 (78) 1362 (89)
Unknown 9 (22) 521 (25)
No. of high risk patients* (%) 38 (93) 1148 (56) ,0.001
NSAIDs and cyclo-oxygenase 2 inhibitors (%):
No NSAIDs 25 (61) 747 (36) ,0.001
NSAIDs with low-dose aspirin 3 (7) 98 (5) 0.45
NSAIDs without low-dose aspirin 6 (15) 966 (47) ,0.001
Cyclo-oxygenase 2 inhibitors with low-dose aspirin 0 30 (1) 1.00
Cyclo-oxygenase 2 inhibitors without low-dose aspirin 7 (17) 257 (12) 0.38
Acetaminophen (%) 14 (34) 624 (30) 0.60
Low-dose aspirin alone (%) 13 (32) 102 (5) ,0.001
Low-dose aspirin, clopidogrel, dipyridamole{ 18 (44) 236 (11) ,0.001
Anticoagulants{ (%) 13 (32) 103 (5) ,0.001
Family history of CV events, no. (%) 22 (71) 824 (55) 0.07
Treatment for RA (%):
No DMARDs 8 (20) 307 (15) 0.38
Methotrexate 14 (34) 1224 (59) ,0.001
Corticosteroids 16 (39) 432 (21) 0.01
Other DMARDs 9 (22) 373 (18) 0.53
Combination of DMARDs1 10 (24) 501 (24) 1.00
Biologicals" 5 (12) 322 (16) 0.06
Gastroprotection** (%) 19 (46) 895 (43) 0.73
Current or previous smoker (%) 32 (78) 1308 (64) 0.06
Antihypertensive drugs (%) 25 (61) 666 (32) ,0.001
Oral diabetic drugs or insulin (%) 4 (10) 130 (6) 0.33
Statins (%) 18 (44) 251 (12) ,0.001
*High risk: higher age and/or previous GI event.
{Low-dose aspirin, clopidogrel and dipyridamole are used in secondary prevention for CV event.
{Anticoagulants: aspirin not included.
1Combination of DMARDs: two or more DMARDs, corticosteroids included.
"Biologicals: adalimumab, infliximab, etanercept and anakinra.
**Gastroprotection: proton pump inhibitors (PPIs), prostaglandin analogue and high dose of H2 antagonists (other: PA or H2A) and
cyclo-oxygenase 2 inhibitors.
DMARDs, disease-modifying antirheumatic drugs; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs.
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